Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model

Amélie Descheemaeker, Hervé Poras, Michel Wurm, Philippe Luccarini, Tanja Ouimet, Radhouane Dallel

Open source

DOI
10.1093/brain/awac139
Published
2022-04-12
Container
Brain
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/brain/awac139,
  title = {Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model},
  author = {Amélie Descheemaeker and Hervé Poras and Michel Wurm and Philippe Luccarini and Tanja Ouimet and Radhouane Dallel},
  year = {2022},
  journal = {Brain},
  doi = {10.1093/brain/awac139},
  url = {https://doi.org/10.1093/brain/awac139}
}

RIS

TY  - JOUR
TI  - Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model
AU  - Amélie Descheemaeker
AU  - Hervé Poras
AU  - Michel Wurm
AU  - Philippe Luccarini
AU  - Tanja Ouimet
AU  - Radhouane Dallel
PY  - 2022
JO  - Brain
DO  - 10.1093/brain/awac139
UR  - https://doi.org/10.1093/brain/awac139
ER  - 

APA

Descheemaeker, A., Poras, H., Wurm, M., Luccarini, P., Ouimet, T., & Dallel, R. (2022). Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model. Brain. https://doi.org/10.1093/brain/awac139

Source records